These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37419907)

  • 1. Kinome-wide CRISPR-Cas9 knockout screens revealed PLK1 as a therapeutic target for osteosarcoma.
    Wang R; Wang D; Bai X; Guo J; Xia S; Cheng Y; Gu Y; Wang Q; Nie J; Chen D; Liu W; Liang J
    Cell Death Discov; 2023 Jul; 9(1):231. PubMed ID: 37419907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.
    Liu X; Choy E; Harmon D; Yang S; Yang C; Mankin H; Hornicek FJ; Duan Z
    Anticancer Drugs; 2011 Jun; 22(5):444-53. PubMed ID: 21399492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic screening for potential therapeutic targets in osteosarcoma through a kinome-wide CRISPR-Cas9 library.
    Wu Y; Zhou L; Wang Z; Wang X; Zhang R; Zheng L; Kang T
    Cancer Biol Med; 2020 Aug; 17(3):782-794. PubMed ID: 32944406
    [No Abstract]   [Full Text] [Related]  

  • 4. Lentiviral shRNA screen of human kinases identifies PLK1 as a potential therapeutic target for osteosarcoma.
    Duan Z; Ji D; Weinstein EJ; Liu X; Susa M; Choy E; Yang C; Mankin H; Hornicek FJ
    Cancer Lett; 2010 Jul; 293(2):220-9. PubMed ID: 20144850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual targeting of Polo-like kinase 1 and baculoviral inhibitor of apoptosis repeat-containing 5 in TP53-mutated hepatocellular carcinoma.
    Li Y; Zhao ZG; Luo Y; Cui H; Wang HY; Jia YF; Gao YT
    World J Gastroenterol; 2020 Aug; 26(32):4786-4801. PubMed ID: 32921957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Polo-like kinase 1 in SMARCB1 deleted atypical teratoid rhabdoid tumor.
    Alimova I; Pierce AM; Harris P; Donson A; Birks DK; Prince E; Balakrishnan I; Foreman NK; Kool M; Hoffman L; Venkataraman S; Vibhakar R
    Oncotarget; 2017 Nov; 8(57):97290-97303. PubMed ID: 29228610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53.
    Van den Bossche J; Deben C; De Pauw I; Lambrechts H; Hermans C; Deschoolmeester V; Jacobs J; Specenier P; Pauwels P; Vermorken JB; Peeters M; Lardon F; Wouters A
    Mol Oncol; 2019 May; 13(5):1196-1213. PubMed ID: 30859681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The mitotic regulator polo-like kinase 1 as a potential therapeutic target for c-Myc-overexpressing canine osteosarcomas.
    Gola C; Licenziato L; Accornero P; Iussich S; Morello E; Buracco P; Modesto P; Aresu L; De Maria R
    Vet Comp Oncol; 2022 Dec; 20(4):890-900. PubMed ID: 36054794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance.
    Sero V; Tavanti E; Vella S; Hattinger CM; Fanelli M; Michelacci F; Versteeg R; Valsasina B; Gudeman B; Picci P; Serra M
    Invest New Drugs; 2014 Dec; 32(6):1167-80. PubMed ID: 25193492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PLK1 Inhibition Targets Myc-Activated Malignant Glioma Cells Irrespective of Mismatch Repair Deficiency-Mediated Acquired Resistance to Temozolomide.
    Higuchi F; Fink AL; Kiyokawa J; Miller JJ; Koerner MVA; Cahill DP; Wakimoto H
    Mol Cancer Ther; 2018 Dec; 17(12):2551-2563. PubMed ID: 30217967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polo-Like Kinase 1 Regulates Chromosomal Instability and Paclitaxel Resistance in Breast Cancer Cells.
    Quan M; Oh Y; Cho SY; Kim JH; Moon HG
    J Breast Cancer; 2022 Jun; 25(3):178-192. PubMed ID: 35775700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinome inhibition reveals a role for polo-like kinase 1 in targeting post-transcriptional control in cancer.
    Al-Qahtani QH; Moghrabi WN; Al-Yahya S; Al-Haj L; Al-Saif M; Mahmoud L; Al-Mohanna F; Al-Souhibani N; Alaiya A; Hitti E; Khabar KSA
    Mol Oncol; 2021 Aug; 15(8):2120-2139. PubMed ID: 33411958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms.
    Nguyen T; Parker R; Hawkins E; Holkova B; Yazbeck V; Kolluri A; Kmieciak M; Rahmani M; Grant S
    Oncotarget; 2017 May; 8(19):31478-31493. PubMed ID: 28416758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytotoxic mechanism of PLK1 inhibitor GSK461364 against osteosarcoma: Mitotic arrest, apoptosis, cellular senescence, and synergistic effect with paclitaxel.
    Chou YS; Yen CC; Chen WM; Lin YC; Wen YS; Ke WT; Wang JY; Liu CY; Yang MH; Chen TH; Liu CL
    Int J Oncol; 2016 Mar; 48(3):1187-94. PubMed ID: 26794530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR-Mediated Kinome Editing Prioritizes a Synergistic Combination Therapy for
    Yang Z; Liang SQ; Yang H; Xu D; Bruggmann R; Gao Y; Deng H; Berezowska S; Hall SRR; Marti TM; Kocher GJ; Zhou Q; Schmid RA; Peng RW
    Cancer Res; 2021 Jun; 81(11):3121-3133. PubMed ID: 33685992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AURKA and PLK1 inhibition selectively and synergistically block cell cycle progression in diffuse midline glioma.
    Metselaar DS; du Chatinier A; Meel MH; Ter Huizen G; Waranecki P; Goulding JR; Bugiani M; Koster J; Kaspers GJL; Hulleman E
    iScience; 2022 Jun; 25(6):104398. PubMed ID: 35637734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.
    Ferrarotto R; Goonatilake R; Yoo SY; Tong P; Giri U; Peng S; Minna J; Girard L; Wang Y; Wang L; Li L; Diao L; Peng DH; Gibbons DL; Glisson BS; Heymach JV; Wang J; Byers LA; Johnson FM
    Clin Cancer Res; 2016 Apr; 22(7):1674-1686. PubMed ID: 26597303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas.
    Hu K; Lee C; Qiu D; Fotovati A; Davies A; Abu-Ali S; Wai D; Lawlor ER; Triche TJ; Pallen CJ; Dunn SE
    Mol Cancer Ther; 2009 Nov; 8(11):3024-35. PubMed ID: 19887553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
    Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
    Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Cereblon Modulator CC-885 Induces CRBN- and p97-Dependent PLK1 Degradation and Synergizes with Volasertib to Suppress Lung Cancer.
    Li L; Xue W; Shen Z; Liu J; Hu M; Cheng Z; Wang Y; Chen Y; Chang H; Liu Y; Liu B; Zhao J
    Mol Ther Oncolytics; 2020 Sep; 18():215-225. PubMed ID: 32728610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.